Who
David Kirn
Director and Officer
Company insider
Files Form 4 as: Chief Executive Officer, 4D Molecular Therapeutics.
In numbers
- Trades disclosed
- 59
- Buys
- 0
- Sells
- 23
- Bought
- $0
- Sold
- $17.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 8 Mar 2021
- Last trade
- 5 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 7 Oct 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $750K58,061 at $12.92 | filing |
| 5 Oct 2026filed 7 Oct 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,702272 at $13.61 | filing |
| 14 Sep 2026filed 16 Sep 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $811K58,333 at $13.90 | filing |
| 14 Sep 2026filed 16 Sep 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $811K58,333 at $13.90 | filing |
| 19 Aug 2026filed 21 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Code M | $207K50,000 at $4.14 | filing |
| 19 Aug 2026filed 21 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $663K43,149 at $15.36 | filing |
| 19 Aug 2026filed 21 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $426K25,927 at $16.42 | filing |
| 19 Aug 2026filed 21 Aug 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Code M | $207K50,000 at $4.14 | filing |
| 19 Aug 2026filed 21 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $663K43,149 at $15.36 | filing |
| 19 Aug 2026filed 21 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $426K25,927 at $16.42 | filing |
| 4 Aug 2026filed 5 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $275K26,842 at $10.23 | filing |
| 4 Aug 2026filed 5 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $275K26,842 at $10.23 | filing |
| 3 Aug 2026filed 4 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $125K12,415 at $10.05 | filing |
| 3 Aug 2026filed 4 Aug 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $125K12,415 at $10.05 | filing |
| 10 Jul 2026filed 14 Jul 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $184K15,283 at $12.01 | filing |
| 10 Jul 2026filed 14 Jul 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,673442 at $12.84 | filing |
| 10 Jul 2026filed 14 Jul 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $184K15,283 at $12.01 | filing |
| 10 Jul 2026filed 14 Jul 2026 | FDMT 4D Molecular TherapeuticsBiotechnology | SEC FORM 4 Sold | $5,675442 at $12.84 | filing |
News
Critical Contrast: 4D Molecular Therapeutics (NASDAQ:FDMT) & Celldex Therapeutics (NASDAQ:CLDX)FDMT · tickerreport.com · 25 Oct 2026Analyzing GeoVax Labs (NASDAQ:GOVX) & 4D Molecular Therapeutics (NASDAQ:FDMT)FDMT · themarketsdaily.com · 24 Oct 2026Contrasting 4D Molecular Therapeutics (NASDAQ:FDMT) and Sangamo Therapeutics (NASDAQ:SGMO)FDMT · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name David Kirn; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.